WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 2, 2018--
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of therapeutics
using its proprietary mucus-penetrating particle (MPP) technology,
announced today that it has commenced an underwritten public offering of
7,500,000 shares of its common stock. Kala also intends to grant the
underwriters of the offering an option for a period of 30 days to
purchase up to an additional 1,125,000 shares of common stock offered in
the public offering at the public offering price, less the underwriting
discount. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed or as to the actual size or terms of the offering.
J.P. Morgan, BofA Merrill Lynch and Jefferies will act as joint
bookrunning managers for the offering. Cantor Fitzgerald & Co. is
serving as lead manager for the offering, and Wedbush PacGrow and
Oppenheimer & Co. Inc. are acting as co-managers for the offering.
The shares are being offered by Kala pursuant to a shelf registration
statement (including a prospectus) that was previously filed with and
declared effective by the U.S. Securities and Exchange Commission
(“SEC”). The offering will be made only by means of the written
prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement relating to
and describing the terms of the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to the offering may also be obtained from: J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204;
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email
or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Kala Pharmaceuticals
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary MPP technology,
with an initial focus on the treatment of eye diseases. Kala has applied
the MPP technology to a corticosteroid, LE, designed for ocular
applications, resulting in recently approved INVELTYS for the treatment
of inflammation and pain following ocular surgery and its lead product
candidate, KPI-121 0.25%, for the temporary relief of the signs and
symptoms of dry eye disease.
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, that involve
substantial risks and uncertainties including statements regarding
whether or not Kala will be able to raise capital through the sale of
shares of common stock, the final terms of the proposed offering, market
and other conditions, the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally. There can be no assurance that Kala will be able to
complete the proposed public offering on the anticipated terms, or at
all. You should not place undue reliance on these forward-looking
statements. Additional risks and uncertainties relating to the proposed
offering, Kala and its business can be found under the caption “Risk
Factors” in the Company's most recently filed Quarterly Report on Form
10-Q, the preliminary prospectus supplement to be filed in connection
with proposed offering and other filings the Company makes with the SEC.
All information in this press release is as of the date of the release
and should not be relied upon as representing the Company’s views as of
any subsequent date, and Kala undertakes no duty to update this
information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181002006065/en/
Source: Kala Pharmaceuticals, Inc.